Trauma News and Research

RSS

UCSF's ACT program helps amputees reach their athletic goals

Carlos Gonzalez stands out from an athletic group gathered on a grassy field at the UCSF Mission Bay campus. The gregarious 32-year-old sports a stylish fauxhawk and walks with a confident yet understated swagger. He's training to become a mixed martial arts (MMA) fighter.

6 Jun 2012

D-cycloserine may increase response to PTSD psychotherapy

Posttraumatic stress disorder (PTSD) is among the most common, distressing, and disabling medical consequences of combat or other extremely stressful life events. The first-line treatment for PTSD is exposure therapy, a type of behavioral therapy where patients confront their fears in a safe environment. Although it is an effective treatment, many patients still experience symptoms after treatment and there is a relatively high drop-out rate.

5 Jun 2012

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Baxter International Inc. today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham's gene therapy technology.

From Baxter International Inc. 5 Jun 2012

Regular and moderate exercise most beneficial for cardiovascular health

Micah True, legendary ultra-marathoner, died suddenly while on a routine 12-mile training run March 27, 2012. The mythic Caballo Blanco in the best-selling book, Born to Run, True would run as far as 100 miles in a day. On autopsy his heart was enlarged and scarred; he died of a lethal arrhythmia (irregularity of the heart rhythm). Although speculative, the pathologic changes in the heart of this 58 year-old veteran extreme endurance athlete may have been manifestations of "Phidippides cardiomyopathy," a condition caused by chronic excessive endurance exercise.

4 Jun 2012

Akron General Medical Center to install Brainsuite iMRI and iCT integrated neurosurgical suites

Brainlab, a manufacturer of software-driven systems for targeted, less-invasive medical treatments, announced today that Akron General Medical Center will install both Brainsuite iMRI and iCT, making it one of only a handful of hospitals in the world to offer both solutions.

2 Jun 2012

HealthSouth to build comprehensive physical rehabilitation hospital in greater Orlando

HealthSouth Corporation today announced it has received permission from the state to proceed with building a comprehensive physical rehabilitation hospital in the greater Orlando, Fla., market. The 50-bed hospital will provide comprehensive physical rehabilitation to patients who have experienced stroke, trauma, brain and orthopedic injuries or other major illness or injuries.

2 Jun 2012

Exercise reduces expression of cytokines and alleviates neuropathic pain

Exercise helps to alleviate pain related to nerve damage (neuropathic pain) by reducing levels of certain inflammation-promoting factors, suggests an experimental study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

ENTA announces availability of first non-invasive oral cancer prevention test

Oral cancer is one of the few cancers still on the rise, claiming the lives of as many Americans as melanoma and has shown a recent increase in young, non-smokers. The important news is that oral cancer can now be prevented.

2 Jun 2012

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

2 Jun 2012

Amarantus to announce results from preclinical study of new protein therapy for TBI

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., announced today that its latest joint venture target, Amarantus BioSciences, Inc., expects to announce the results of a preclinical study evaluating the potential of its new protein therapy as a treatment for Traumatic Brain Injury (TBI).

2 Jun 2012

College undergraduates less upset than expected by questionnaires about sex, trauma

Research on sex and trauma faces an ethical dilemma: how can we find out more about the effects of such psychologically sensitive topics without hurting the people who participate in the study?

1 Jun 2012

JSUMC completes first procedure with TAVR

Jersey Shore University Medical Center proudly announces the completion of its first procedure with the Transcatheter Aortic Valve Replacement (TAVR), the latest minimally-invasive, life-saving innovation for non-operative patients with critical aortic stenosis.

1 Jun 2012

RXi’s RXI-109 IND receives FDA clearance to proceed into clinical trials

RXi Pharmaceuticals Corporation today announced that it has received clearance for its investigational new drug application (IND) from the U.S. Food and Drug Administration (FDA) to initiate clinical trials with RXI-109, a self-delivering RNAi compound that selectively targets Connective Tissue Growth Factor.

1 Jun 2012

UCSB creates synthetic platelets for various biomedical applications

Synthetic platelets have been developed by UC Santa Barbara researchers, in collaboration with researchers at Scripps Research Institute and Sanford-Burnham Institute in La Jolla, Calif. Their findings are published in the journal Advanced Materials in a paper titled "Platelet Mimetic Particles for Targeting Thrombi in Flowing Blood."

31 May 2012

Exendin-4 significantly minimizes damage in TBI animal models

Although the death toll is relatively low for people who suffer from traumatic brain injury (TBI), it can have severe, life-long consequences for brain function. TBI can impair a patient's mental abilities, impact memory and behavior, and lead to dramatic personality changes. And long-term medical treatment carries a high economic cost.

30 May 2012

ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

Baxter International Inc. today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids.

From Baxter International Inc. 28 May 2012

UCLA Face Transplantation Program seeks candidates for clinical trial

The UCLA Health System has launched the UCLA Face Transplantation Program, the first surgical program of its kind in the western United States and one of only a handful in the nation.

25 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012

Tips to protect against sun's harmful rays

With backyard, beach and barbeque season upon us and the season's first heat wave right around the corner, a family physician at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM) is reminding everyone to "Go SLoW" to enjoy a healthy summer season.

25 May 2012

New trauma intervention halves psychological distress in child war and sexual abuse victims

A new psychological intervention has been shown to more than halve the trauma experienced by child victims of war, rape and sexual abuse.

24 May 2012

Trauma News and Research

UCSF's ACT program helps amputees reach their athletic goals

D-cycloserine may increase response to PTSD psychotherapy

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Regular and moderate exercise most beneficial for cardiovascular health

Akron General Medical Center to install Brainsuite iMRI and iCT integrated neurosurgical suites

HealthSouth to build comprehensive physical rehabilitation hospital in greater Orlando

Exercise reduces expression of cytokines and alleviates neuropathic pain

ENTA announces availability of first non-invasive oral cancer prevention test

Lilly, Kowa announce results from PREVAIL U.S. study

Amarantus to announce results from preclinical study of new protein therapy for TBI

College undergraduates less upset than expected by questionnaires about sex, trauma

JSUMC completes first procedure with TAVR

RXi’s RXI-109 IND receives FDA clearance to proceed into clinical trials

UCSB creates synthetic platelets for various biomedical applications

Exendin-4 significantly minimizes damage in TBI animal models

ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

UCLA Face Transplantation Program seeks candidates for clinical trial

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Tips to protect against sun's harmful rays

New trauma intervention halves psychological distress in child war and sexual abuse victims

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News